Lv11
38 积分 2022-08-13 加入
Serum and Tumor PD-L1 Expression and Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma
6小时前
已完结
Updates in systemic therapy for refractory thyroid carcinoma - targeted agents, immunotherapy, and chemotherapy
6小时前
已完结
BRAF/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: A systematic review and Meta-Analysis
22天前
已完结
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
26天前
已完结
Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer
3个月前
已完结
BRAF(V600E)基因突变甲状腺癌诊疗专家共识（2026版）
3个月前
已完结
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer
3个月前
已完结
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer
3个月前
已完结
Treatment of Unresectable BRAF V600E, TERT-Mutated Differentiated Papillary Thyroid Cancer With Dabrafenib and Trametinib
3个月前
已完结
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
3个月前
已完结
皖公网安备34019202002308
